A fragment-based approach to assess the ligandability of ArgB, ArgC, ArgD and ArgF in the L-arginine biosynthetic pathway of Mycobacterium tuberculosis

[1]  H. Vogel,et al.  Glutamic γ-Semialdehyde and Δ1-Pyrroline-5-carboxylic Acid, Intermediates in the Biosynthesis of Proline1,2 , 1952 .

[2]  Shane A. Seabrook,et al.  Determination of the Structure of the Catabolic N-Succinylornithine Transaminase (AstC) from Escherichia coli , 2013, PloS one.

[3]  Thomas R. Ioerger,et al.  Comprehensive Essentiality Analysis of the Mycobacterium tuberculosis Genome via Saturating Transposon Mutagenesis , 2017, mBio.

[4]  A. Albrecht,et al.  ACETYLORNITHINE DELTA-TRANSAMINASE. PARTIAL PURIFICATION AND REPRESSION BEHAVIOR. , 1964, The Journal of biological chemistry.

[5]  T. Blundell,et al.  Structure-guided fragment-based drug discovery at the synchrotron: screening binding sites and correlations with hotspot mapping , 2019, Philosophical Transactions of the Royal Society A.

[6]  A. Palmer,et al.  A Relaxation-Compensated Carr−Purcell−Meiboom−Gill Sequence for Characterizing Chemical Exchange by NMR Spectroscopy , 1999 .

[7]  Andries J. van Tonder,et al.  Arginine-deprivation–induced oxidative damage sterilizes Mycobacterium tuberculosis , 2018, Proceedings of the National Academy of Sciences.

[8]  E. Rubin,et al.  Feast or famine: the host–pathogen battle over amino acids , 2013, Cellular microbiology.

[9]  C. Vilchèze,et al.  The Isoniazid Paradigm of Killing, Resistance, and Persistence in Mycobacterium tuberculosis. , 2019, Journal of molecular biology.

[10]  M. Hyvönen,et al.  T7 vectors with modified T7lac promoter for expression of proteins in Escherichia coli. , 1996, Analytical biochemistry.

[11]  Bernd Meyer,et al.  Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectroscopy. , 1999, Angewandte Chemie.

[12]  A. Surolia,et al.  An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: Implications to a novel combinatorial therapy , 2018, EMBO molecular medicine.

[13]  Olivier Sperandio,et al.  Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. , 2014, Journal of medicinal chemistry.

[14]  Harren Jhoti,et al.  Twenty years on: the impact of fragments on drug discovery , 2016, Nature Reviews Drug Discovery.

[15]  T. Blundell,et al.  Fragment-based discovery of a new class of inhibitors targeting mycobacterial tRNA modification , 2019, bioRxiv.

[16]  Clemens Vonrhein,et al.  Data processing and analysis with the autoPROC toolbox , 2011, Acta crystallographica. Section D, Biological crystallography.

[17]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[18]  Bing Chen,et al.  A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis , 2002, Nature Medicine.

[19]  N. Connell,et al.  Modulation of J774.1 Macrophage l-Arginine Metabolism by Intracellular Mycobacterium bovis BCG , 2003, Infection and Immunity.

[20]  Graeme Winter,et al.  xia2: an expert system for macromolecular crystallography data reduction , 2010 .

[21]  W. Jacobs,et al.  Protection Elicited by Two Glutamine Auxotrophs of Mycobacterium tuberculosis and In Vivo Growth Phenotypes of the Four Unique Glutamine Synthetase Mutants in a Murine Model , 2006, Infection and Immunity.

[22]  R. Wintjens,et al.  Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening. , 2020, European journal of medicinal chemistry.

[23]  W. Jacobs,et al.  Attenuation of and Protection Induced by a Leucine Auxotroph of Mycobacterium tuberculosis , 2000, Infection and Immunity.

[24]  P. Zwart,et al.  Towards automated crystallographic structure refinement with phenix.refine , 2012, Acta crystallographica. Section D, Biological crystallography.

[25]  Yasmin Lau.  Fragment-based discovery of a new class of inhibitors targeting mycobacterial tRNA modification , 2019 .

[26]  J. Parkhill,et al.  Essential roles of methionine and S-adenosylmethionine in the autarkic lifestyle of Mycobacterium tuberculosis , 2015, Proceedings of the National Academy of Sciences.

[27]  Peter Canning,et al.  Fragment-based target screening as an empirical approach to prioritising targets: a case study on antibacterials. , 2020, Drug discovery today.

[28]  Thomas R. Ioerger,et al.  Genome Analysis of Multi- and Extensively-Drug-Resistant Tuberculosis from KwaZulu-Natal, South Africa , 2009, PloS one.

[29]  M. James,et al.  Crystal structure of N-acetyl-gamma-glutamyl-phosphate reductase from Mycobacterium tuberculosis in complex with NADP(+). , 2006, Journal of molecular biology.

[30]  Robert H Bates,et al.  Screening of a Novel Fragment Library with Functional Complexity against Mycobacterium tuberculosis InhA , 2018, ChemMedChem.

[31]  N. Connell,et al.  Amino Acid Transport and Metabolism in Mycobacteria: Cloning, Interruption, and Characterization of anl-Arginine/γ-Aminobutyric Acid Permease inMycobacterium bovis BCG , 2000, Journal of bacteriology.

[32]  B. Veyret,et al.  l-Arginine Availability Modulates Local Nitric Oxide Production and Parasite Killing in Experimental Trypanosomiasis , 2000, Infection and Immunity.

[33]  T. Blundell,et al.  Targeting tuberculosis using structure-guided fragment-based drug design. , 2017, Drug discovery today.

[34]  Y. Poquet,et al.  Nitrogen metabolism in Mycobacterium tuberculosis physiology and virulence , 2014, Nature Reviews Microbiology.

[35]  G. Bancroft,et al.  Characterization of Auxotrophic Mutants ofMycobacterium tuberculosis and Their Potential as Vaccine Candidates , 2001, Infection and Immunity.

[36]  T. Blundell,et al.  Fragment-Based Design of Mycobacterium tuberculosis InhA Inhibitors , 2019, Journal of medicinal chemistry.

[37]  R. Wintjens,et al.  Fragment-based optimized EthR inhibitors with in vivo ethionamide boosting activity. , 2020, ACS infectious diseases.

[38]  V. Guallar,et al.  Mechanism of thermal decomposition of carbamoyl phosphate and its stabilization by aspartate and ornithine transcarbamoylases , 2008, Proceedings of the National Academy of Sciences.

[39]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[40]  T. Blundell,et al.  Using a fragment-based approach to identify alternative chemical scaffolds targeting dihydrofolate reductase from Mycobacterium tuberculosis. , 2020, ACS infectious diseases.

[41]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[42]  T. Blundell,et al.  Mycobacterial OtsA Structures Unveil Substrate Preference Mechanism and Allosteric Regulation by 2-Oxoglutarate and 2-Phosphoglycerate , 2019, mBio.

[43]  Tom L. Blundell,et al.  Development of Inhibitors against Mycobacterium abscessus tRNA (m1G37) Methyltransferase (TrmD) Using Fragment-Based Approaches , 2019, Journal of medicinal chemistry.